Testing A New Experimental Drug To Raise Good Cholesterol Level.
An experiential downer that raises HDL, or "good," cholesterol seems to have passed an prime hurdle by proving safe in preliminary trials. Although the trial was primarily designed to looks at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual assembly in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and portion LDL, HDL's evil twin, almost in half natural-breast-success.club. "We saw very encouraging reductions in clinical events," said Dr Christopher Cannon, premier danseur author of the study, which also appears in the Nov 18, 2010 subject of the New England Journal of Medicine.
A big study to sanction the results would take four to five years to complete so the drug is still years away from market who is a cardiologist with Brigham and Women's Hospital in Boston. Other experts are intrigued by the findings, but note that the probing is still in very at stages kontol. "There are a lot of people in the prevention/lipid field that are simultaneously excited and leery," said Dr Howard Weintraub, clinical headman of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.
Added Dr John C LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: "It's very initial but it's prominent because the hindmost drug out of the barrel of this type was not a success. This looks adulate a better drug, but it's not definitive by any means. Don't take this to the bank".
LaRosa was referring to torcetrapib, which, be fond of anacetrapib, belongs to the class of drugs known as cholesterol ester transport protein (CETP) inhibitors. A large trial on torcetrapib was killed after investigators found an increased hazard of death and other cardiovascular outcomes. "I would be more excited about anacetrapib if I hadn't seen what happened to its cousin torcetrapib. Torcetrapib raised HDL astoundingly but that was unequivocally neutralized by the dilate in cardiovascular events".
Showing posts with label trial. Show all posts
Showing posts with label trial. Show all posts
Sunday, 29 July 2018
Saturday, 14 January 2017
Prevention Of Cardiovascular Diseases By Dietary Supplements
Prevention Of Cardiovascular Diseases By Dietary Supplements.
Regular doses of the dietary addendum Coenzyme Q10 half-tone in half the death rate of patients trial from advanced heart failure, in a randomized double-blind trial in May 2013. Researchers also reported a significant ebb in the number of hospitalizations for heart failure patients being treated with Coenzyme Q10 (CoQ10) prostate mage and milking health. About 14 percent of patients taking the annexe suffered from a major cardiovascular event that required sickbay treatment, compared with 25 percent of patients receiving placebos.
In heart failure, the bravery becomes weak and can no longer pump enough oxygen- and nutrient-rich blood throughout the body. Patients often sustain fatigue and breathing problems as the heart enlarges and pumps faster in an effort to into the body's needs pregnancy. The study is scheduled to be presented Saturday at the annual meeting of the Heart Failure Association of the European Society of Cardiology, in Lisbon, Portugal.
And "CoQ10 is the firstly medication to rectify survival in chronic heart failure since ACE inhibitors and beta blockers more than a decade ago and should be added to example heart failure therapy," lead researcher Svend Aage Mortensen, a professor with the Heart Center at Copenhagen University Hospital, in Denmark, said in a community tidings release. While randomized clinical trails are considered the "gold standard" of studies, because this unusual study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.
American cardiologists greeted the reported findings with heedful optimism. "This is a study that is very positive but requires replication in a second confirmatory trial," said Dr Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, and a spokesman for the American Heart Association. Fonarow respected that earlier, smaller trials with Coenzyme Q10 have produced mongrel results.
And "Some studies have shown no effect, while other studies have shown some improvement, but not nearly the awe-inspiring effects displayed in this trial. Coenzyme Q10 occurs not unexpectedly in the body. It functions as an electron carrier in cellular mitochondria (the cell's "powerhouse") to servant convert food to energy. It also is a powerful antioxidant, and has become a fashionable over-the-counter dietary supplement.
Regular doses of the dietary addendum Coenzyme Q10 half-tone in half the death rate of patients trial from advanced heart failure, in a randomized double-blind trial in May 2013. Researchers also reported a significant ebb in the number of hospitalizations for heart failure patients being treated with Coenzyme Q10 (CoQ10) prostate mage and milking health. About 14 percent of patients taking the annexe suffered from a major cardiovascular event that required sickbay treatment, compared with 25 percent of patients receiving placebos.
In heart failure, the bravery becomes weak and can no longer pump enough oxygen- and nutrient-rich blood throughout the body. Patients often sustain fatigue and breathing problems as the heart enlarges and pumps faster in an effort to into the body's needs pregnancy. The study is scheduled to be presented Saturday at the annual meeting of the Heart Failure Association of the European Society of Cardiology, in Lisbon, Portugal.
And "CoQ10 is the firstly medication to rectify survival in chronic heart failure since ACE inhibitors and beta blockers more than a decade ago and should be added to example heart failure therapy," lead researcher Svend Aage Mortensen, a professor with the Heart Center at Copenhagen University Hospital, in Denmark, said in a community tidings release. While randomized clinical trails are considered the "gold standard" of studies, because this unusual study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.
American cardiologists greeted the reported findings with heedful optimism. "This is a study that is very positive but requires replication in a second confirmatory trial," said Dr Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, and a spokesman for the American Heart Association. Fonarow respected that earlier, smaller trials with Coenzyme Q10 have produced mongrel results.
And "Some studies have shown no effect, while other studies have shown some improvement, but not nearly the awe-inspiring effects displayed in this trial. Coenzyme Q10 occurs not unexpectedly in the body. It functions as an electron carrier in cellular mitochondria (the cell's "powerhouse") to servant convert food to energy. It also is a powerful antioxidant, and has become a fashionable over-the-counter dietary supplement.
Monday, 16 May 2016
PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer
PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer.
A knowledge that urologists had hoped would transform it reasonable to distinguish men with prostate cancer who need treatment from those who would only need watchful waiting didn't accomplish well, researchers report. The technique, called PSA kinetics, measures changes in the figure at which the prostate gland produces a protein called prostate-specific antigen helped.top. A significant burgeon in PSA kinetics, measured by the time during which PSA production doubles or increases at a high-speed rate, is supposed to indicate the need for treatment, by radiation therapy or surgery.
PSA kinetics has prolonged been used to measure the effectiveness of treatment top. A number of cancer centers have started to use it as a workable method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be left alone.
Recent studies indicating that many men with slow-growing prostate cancers subject oneself to unnecessary treatment have given imperativeness to the search for such a tool, especially considering that side effects of treatment can include incontinence and impotence. But the mull over indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr Ashley E Ross, a urology abiding at the Johns Hopkins University Brady Urological Institute, and standard author of a report on the technique published online May 3 in the Journal of Clinical Oncology.
The discharge describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer - the big-hearted that often doesn't require treatment - for an average of 2,9 years. The results of PSA tests were compared with biopsies - fabric samples - that cautious the progression of the cancers.
The trial is part of a study, under supervision of Dr H Ballentine Carter, superintendent of the division of adult urology at the Brady Urological Institute, that began in 1994. Men in the whack had PSA tests every six months and biopsies every year.
A knowledge that urologists had hoped would transform it reasonable to distinguish men with prostate cancer who need treatment from those who would only need watchful waiting didn't accomplish well, researchers report. The technique, called PSA kinetics, measures changes in the figure at which the prostate gland produces a protein called prostate-specific antigen helped.top. A significant burgeon in PSA kinetics, measured by the time during which PSA production doubles or increases at a high-speed rate, is supposed to indicate the need for treatment, by radiation therapy or surgery.
PSA kinetics has prolonged been used to measure the effectiveness of treatment top. A number of cancer centers have started to use it as a workable method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be left alone.
Recent studies indicating that many men with slow-growing prostate cancers subject oneself to unnecessary treatment have given imperativeness to the search for such a tool, especially considering that side effects of treatment can include incontinence and impotence. But the mull over indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr Ashley E Ross, a urology abiding at the Johns Hopkins University Brady Urological Institute, and standard author of a report on the technique published online May 3 in the Journal of Clinical Oncology.
The discharge describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer - the big-hearted that often doesn't require treatment - for an average of 2,9 years. The results of PSA tests were compared with biopsies - fabric samples - that cautious the progression of the cancers.
The trial is part of a study, under supervision of Dr H Ballentine Carter, superintendent of the division of adult urology at the Brady Urological Institute, that began in 1994. Men in the whack had PSA tests every six months and biopsies every year.
Subscribe to:
Posts (Atom)